Alexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. The Company’s product candidates are based on its technology the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled allows for systemic drug delivery. It has two product candidates in active development, AZ-002 and AZ-007. Its product AZ-002 contains Staccato alprazolam as an active ingredient. AZ-002 is indicated for the treatment of Acute Repetitive Seizures. It initiated a Phase IIa proof-of-concept study for AZ-002 in patients with epilepsy. Its product AZ-007 contains Staccato zaleplon as an active ingredient. It is developing AZ-007 for the treatment of insomnia in patients who have difficulty falling asleep, including those patients with middle of the night awakening who have difficulty falling back asleep.